Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's been a good few days for us.
Good buying opportunity
The one positive of MM is a good buying opportunity. Just loaded up this morning.
That is only their employees on the payroll. Much of their product development it outsourced (who knows how many heads are on these teams), their clinical trials will likely be run by a CRO and so on for every needed resource. They will also continually add more employees as they need them. I do agree that they will be acquired, though I think it's more directly involved with having a superb product in a niche market with the high likelihood of disrupting the market share than having limited personnel.
Exactly. Nothing can be discussed or marketed for Titan as of right now. If the Device was CE marked, physicians can discuss the results of how they've used it OUS. Otherwise, it's going to be as Magenetics said - investigator meetings and discussions between Key Opinion Leaders and physicians planned to run the companies trials.
Unless you know that a RS or an acquisition is happening, don't bother posting this. You're just skewing other's view and outlook who are initially looking into Titan and doing DD.
I work in business development and clinical R&D at a med device company in California. First heard about Titan several years ago from my physician buddies who are pioneers with the Da Vinci. Most of them are very interested and invested in Titan, however some are loyal to intuitive and weren't thrilled with the SPORT device/plans when they were brought up to the offices to see it several years ago (granted much has changed).
I started investing in Titan about a year ago and continually add to my position every week. I have also been invested in TRXC based off info from a source of mine. Was a bummer they offered the shares at significant discount, but I continually add to my position there as well.
Intuitive Surgical: Evaluation of technical feasibility and safety of Single-Siteâ„¢ robotic right colectomy: three case reports.
http://www.ncbi.nlm.nih.gov/pubmed/25156297
Intuitive Surgical: Evaluation of technical feasibility and safety of Single-Siteâ„¢ robotic right colectomy: three case reports.
http://www.ncbi.nlm.nih.gov/pubmed/25156297
Good to see others in the industry and in the local area!
Good to have you back. Would like to check out the link if you shoot it my way. Is it FW related or just launched during FW there?
Other medical device and pharma stocks.
What other stocks do you guys have positions in? I value some of your opinions and always looking for new new markets and therapies coming out.
I'm in TRXC and TITXF - though I am now following TITXF more diligently. Lots of things to happen in both companies, and I will continually buy shares in both, but don't write off TRXC off just yet ;)
Hahahaha - Perfectly put. The end.
For everyone else, stop the nonsense on this board and provide some valuable information.
I wasn't implying that there was a sponsor for that specific trial - it appears to be investigator-initiated anyway. Just glad to see Titan is bringing on physicians that are actively performing research to support the movement to single-port surgeries.
Article: Trends in Healthcare Investments and Exits.
Thought you all might be interested to read through and take a look at the data and figures in this article.
Check the device section starting on Page 18. They look at big exit M&A deals broken down by therapeutic area and approval stage. Interesting to see the spread between the top 3 acquirers (Medtronic, Boston Scientific, and Bard) vs other acquirers.
http://www.svb.com/uploadedFiles/Content/Blogs/Healthcare_Report/healthcare-report-2014(1).pdf
Wow! This is great to see - I love that Titan is actively recruiting and bringing doctors on boards that are key opinion leaders and actively performing research and running trials.
Interested to see the paper or early results
Single site surgery paper. Thought you all might be interested in reading.
Here is a single-site surgery paper showing safety for gynecologic procedures. Robot used was Da Vinci.
http://www.sciencedirect.com/science/article/pii/S0002937814008060#
There is nothing from the FDA saying Titan has to perform a 300 patient trial - that was just an example he used.
The FDA has not responded to Titan that we know of. Who knows if they've even filed any pre-sub documents. They haven't even received CE mark, FDA approval is still a little ways out.
Hopefully they want require any human data, and at the worst case if they do, a 50 patient trial where they would already have the data from Europe if they were smart.
This is great!!
Guys, these announcements are great. In the Medical Device industry, if a company is reporting that they are hitting all their milestones, there is not much more than you can ask for. I can't tell you how often projects and milestones get delayed - it's almost guaranteed to happen.
It's awesome to hear that Titan is hitting their milestones. Of course they're going to be tight lipped on everything else, they don't have much else to divulge, nor would they want to divulge anything further.
Everything is on track - THAT IS GOOD NEWS. Of course we still haven't hit anything timelines close to the FDA (Guaranteed there will slight delays then).
Of course the share price will remain stagnant until any major milestones are hit. We're approaching some exciting news in these next 12-18 months. Human testing, CE mark, FDA approval, etc. I don't foresee any issues with this as we're going through 510k and titan would have to try in order to fail to show that is not as effective or more effective than the devices on the market.
Tissue testing, bench testing, animal testing, etc are all necessary but boring items to the public. Regardless,they are hitting milestones on track and moving into some exciting times. If you haven't loaded up now is the time and expect some exciting times Q1 and Q2 of next year and moving forward.
It looks like it's investigator sponsored research / grant. UC Davis running the trial, Intuitive paying for various milestones, results, and paper.
It all depends on what the FDA requests. Since there are already similar devices on the market, the FDA will only require a 510(k) for approval of Titan's device. However, they could submit their 510(k) and the FDA comes back 3-6 months later saying we need clinical human data for some reason. If this happens, then they have to design a trial, do the startup, enroll patients, etc. This could delay their device to market by 1-2 years. They likely only require a small population of < 50 patients and maybe a 30 day follow up as the endpoints of the trial will be based around the effectiveness of the device.
I am not familiar with Titan's timeline as I haven't checked it in a month or so, can someone link to this?
If they have a feeling that the FDA will come back with human data required and they are smart, after they get CE mark they should begin a trial in EU as a contingency plan. If the FDA does come back saying we need data, Voila! they have it already and it puts their device on the market a year or so sooner than if they didn't have that data.
They likely waited until all 3-year follows up data was collected, rather than releasing a paper based one 1 or 2-year follow up then another paper with 3 year follow up.
A Novel Robotic System for Single-port Urologic Surgery: First Clinical Investigation
http://www.sciencedirect.com/science/article/pii/S0302283814006137
Can someone explain what went wrong in TRXC R/S tactic? It doesn't seem like the R/S was the problem, rather uplisting at a market price of half of the previous share price. Can someone explain how this process works? Can companies just choose what share price they want to go public at? Cheers.
Venture Capital. I'd say in my opinion, TITXF has more press and public coverage. However, from the groups that I've talked to on the back end in the industry, TRXC has been looked at far more for those types of investments. Both companies have different strategies and exposure due to this, but that's what makes it exciting. I'm invested in both and want to see both succeed.
Who says the medical community hasn't heard of TRXC? It's huge in many types of industries... medical, VC, etc.
I hope it translates to TITXF. TRXC is doing well. Although I got in before the R/S, I loaded up on some more shares yesterday. Definite buy at this time.
I hope he pulls through. At the end of the day, the company is here to make money for itself and its shareholders.
Looking forward to some gains! My initial shares need to get back to where we were before the R/S. But I loaded up more today, it's a definite buy at it's current PPS.
They are still only doing tissue testing, so they aren't that far along toward FDA approval. FDA approval will still be around the end of 2015 and possibly even later given the FDA's response time lately.
Also,China FDA (CFDA) is becoming much more stringent on their clinical trial data requirements for approval. They're making it really tough for businesses to have an upside of commercialization in China.
I need to stop coming here so often. Some of this things posted on this board I just shake my head at. Seems to be moving away from informative investment and medical device information to nonsense.
I hope you have 200k + shares to retire comfortably.
This is stock will not reach over 100, let alone $500. It's going to get acquired well before then. It will be acquired after market approval in the US and sales for at least a year or two. The share price will likely be below $50 at this point.
I am nearby UCI. They are heavily invested in the Intuitive platform I have not heard word of a partnership or even consideration with Titan from their doctors.
They definitely know. The industry is a small world - they knew well before us/the public knew.
Finally. Time to jump in and ride it up.
Dividend and Split Explanation
Can someone explain how dividend allocations are changed during a split. With the dividend increase we are currently at 3.29/quarter. When the split happens will this dividend be divided by 7x to reflect a proper dividend allocation per share?
Cheers.
I don't see an acquisition happening until the device is FDA approved and they have close to a year of sales under their belt. Big players in the industry are shifting their dollars to acquisitions rather than internal development, but they want to buy a product that is proven (and a business decision that benefits the shareholders) - and they're willing to pay the premium for this.
Public Offering explanation...
Can anyone explain how the public offering share price is decided on and how this correlates with outstanding shares. In the example of TRXC, how can they decide on a public offering that is almost half pps than it was currently trading at? Do the investors just take the loss?
Can't find much to explain how this process works in this situation or in general.
Cheers.
What other company?